Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

2.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

3.

Chemo causes lasting physical decline in breast cancer survivors

4.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

5.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot